Search Results for: G1 Therapeutics Announces Clinical Trial
Articles
December 12, 2016
G1 Therapeutics Announces Clinical Trial Collaboration With Genentech December 12, 2016
G1 Therapeutics recently announced a clinical trial collaboration with Genentech, a member of the Roche Group. A Phase II clinical...
May 7, 2024
Inmagene Announces Completion of Enrollment in Phase 2a Trial of a Nondepleting & Half-Life Extended Anti-OX40 Monoclonal Antibody May 7, 2024
Inmagene Biopharmaceuticals recently announced it completed target enrollment in its Phase 2a trial evaluating IMG-007 in adult patients with AA....
May 1, 2024
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial May 1, 2024
Denali Therapeutics Inc. recently announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium...
April 30, 2024
Biora Therapeutics Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600 April 30, 2024
Biora Therapeutics, Inc. recently announced completion of dosing for the multiple-ascending dose cohorts for its clinical study of BT-600, a...
April 23, 2024
Salubris Biotherapeutics Announces $35 Million in Financing & Provides Pipeline Progress Update April 23, 2024
Salubris Biotherapeutics, Inc. recently announced a new capital infusion of $35 million to fund continued research and development of clinical...
March 26, 2024
Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy in Patients with Rare Inherited Retinal Disease LCA5 March 26, 2024
Opus Genetics recently announced the first cohort has completed dosing in its open-label, dose-escalation Phase 1/2 clinical trial evaluating the...
February 26, 2024
Tenaya Therapeutics Announces Preclinical HDAC6 Inhibitor Data for Heart Failure With Preserved Ejection Fraction February 26, 2024
Tenaya Therapeutics, Inc. recently announced the publication of preclinical research related to Tenaya’s small molecule inhibitors of histone deacetylase 6...
November 29, 2023
BiomX Announces Positive Topline Results From Part 2 of the Phase 1b/2a Trial Evaluating Treatment for Chronic Pulmonary Infections in Patients With Cystic Fibrosis November 29, 2023
BiomX Inc. recently announced positive safety and efficacy results from Part 2 of the Phase 1b/2a trial evaluating the company’s...
October 26, 2023
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy October 26, 2023
Tenaya Therapeutics, Inc. recently announced the US FDA has provided clearance of the company’s Investigational New Drug (IND) application to...
August 14, 2023
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial August 14, 2023
PDS Biotechnology Corporation recently announced the submission to the US FDA of an updated Chemistry, Manufacturing and Controls (CMC) package...
August 8, 2023
Lisata Therapeutics Announces US FDA Orphan Drug Designation Granted for the Treatment of Malignant Glioma August 8, 2023
Lisata Therapeutics, Inc. recently announced the US FDA has granted Orphan Drug Designation to LSTA1, the company’s lead product candidate,...
July 10, 2023
Tonix Pharmaceuticals Announces Initiation of Enrollment in MGH Phase 2 POWER Study of Intranasal Potentiated Oxytocin for the Treatment of Pediatric Obesity July 10, 2023
Tonix Pharmaceuticals Holding Corp. recently announced the first participant was enrolled in the Phase 2 POWER study of TNX-1900 (intranasal...
June 27, 2023
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma June 27, 2023
Harpoon Therapeutics, Inc. recently announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the...
June 14, 2023
PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 & KEYTRUDA in Head & Neck Cancer June 14, 2023
PDS Biotechnology Corporation recently announced it achieved the threshold for efficacy as per investigator assessment in Stage 2 of the...
May 23, 2023
Valo Therapeutics Announces First Patient Dosed With PeptiCRAd-1 - Innovative Immuno-Oncology May 23, 2023
Valo Therapeutics Oy (ValoTx) recently announced the first patient has been treated in its Phase 1 trial of PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus) in three tumor….
March 2, 2023
Checkpoint Therapeutics Announces FDA Filing Acceptance of BLA for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma March 2, 2023
Checkpoint Therapeutics, Inc. recently announced the US FDA has accepted for filing the Biologics License Application (BLA) for cosibelimab, Checkpoint’s investigational anti-PD-L1 antibody….
January 11, 2023
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer January 11, 2023
BioXcel Therapeutics, Inc. recently announced promising top-line data from its Phase 2 trial of BXCL701, the company's investigational, oral innate...
December 16, 2022
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody ADG126 in Combination With Roche’s Standard-of-Care for First-Line Advanced Liver Cancer December 16, 2022
Adagene Inc. recently announced a clinical trial collaboration with Roche to evaluate the triple combination of Adagene’s ADG126 with Roche’s atezolizumab and bevacizumab in first-line treatment of….
November 17, 2022
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor for the Treatment of Vitiligo November 17, 2022
VYNE Therapeutics Inc. recently announced the first subjects have been dosed in a Phase 1a/b clinical trial evaluating VYN201 for...
September 13, 2022
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza September 13, 2022
Cidara Therapeutics, Inc. recently announced the initiation of its Phase 2a trial to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus…..
